On the other hand, the lower MM mutation burden as compared to that observed in CM lesions may justify this clinical observation, whereas the presence of tumor-infiltrating lymphocytes (TILs) could be a predictor of anti PD-L1 response [41]. This evidence concerns the gene CD274 and Miyoshi myopathy.